RareSearch logo

Seattle Children's Hospital Research Institute - Center for Global Infectious Disease Research

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Terry Barrows profile

Terry Barrows

🇹🇷 Turkey

8.6

    Reviewed:

  • - Patient Engagement
  • - 8 weeks August - September 2023
  • - Clinical Research Organization

Impressive patient engagement strategies, significant improvement in recruitment rates.

The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.

Marjorie Stanton profile

Marjorie Stanton

🇸🇦 Saudi Arabia

9

    Reviewed:

  • - Clinical Protocol Design
  • - 6 weeks April - May 2023
  • - Pharmaceutical Company

Comprehensive protocol design, very detailed and precise.

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Manuel Mann profile

Manuel Mann

🇦🇺 Australia

5.4

    Reviewed:

  • - Process Development
  • - 14 weeks June - September 2024
  • - Biotech Company

Process development project faced delays, communication issues.

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.

Daniel Funk II profile

Daniel Funk II

🇮🇹 Italy

8.7

    Reviewed:

  • - Patient Recruitment
  • - 8 weeks March - April 2023
  • - Clinical Research Organization

Highly effective patient recruitment strategies, project completed on time.

The patient recruitment strategies were highly effective, and the project was completed within the agreed timeframe. The team was very professional, and their expertise in patient engagement was evident throughout.

David Windler profile

David Windler

🇮🇳 India

8.9

    Reviewed:

  • - Stability Studies
  • - 18 months January 2023 - June 2024
  • - Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Claude Kirlin-Swift DDS profile

Claude Kirlin-Swift DDS

🇩🇪 Germany

5.6

    Reviewed:

  • - Clinical Data Management
  • - 8 weeks December 2023 - February 2024
  • - Biotech Company

Delayed delivery and lack of communication during the project.

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.

Hector Cruickshank profile

Hector Cruickshank

🇨🇭 Switzerland

9.2

    Reviewed:

  • - Regulatory Strategy Consulting
  • - 4 weeks July - August 2024
  • - Biotech Startup

Thorough and strategic regulatory strategy consulting.

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Kayla Hand profile

Kayla Hand

🇳🇱 Netherlands

5.8

    Reviewed:

  • - Biostatistical Design
  • - 6 weeks February - March 2024
  • - Research Institution

Biostatistical analysis lacked depth, missed key insights.

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Theodore Stokes profile

Theodore Stokes

🇪🇸 Spain

8.8

    Reviewed:

  • - Biostatistical Design
  • - 4 weeks May - June 2023
  • - Research Institution

Excellent biostatistical support, clear and actionable insights.

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Earl Ernser profile

Earl Ernser

🇰🇷 South Korea

8.8

    Reviewed:

  • - Companion Diagnostics Development
  • - 16 weeks January - May 2024
  • - Pharmaceutical Company

High-quality companion diagnostics development, delivered on time.

The development of companion diagnostics was of high quality, and the project was delivered on time. The team's technical expertise and understanding of the regulatory environment were key to the success of the project.